Roivant Sciences Stock Performance
| ROIV Stock | USD 12.69 0.01 0.08% |
Roivant Sciences has a performance score of 6 on a scale of 0 to 100. The company holds a Beta of 0.78, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Roivant Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Roivant Sciences is expected to be smaller as well. Roivant Sciences right now holds a risk of 1.69%. Please check Roivant Sciences maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Roivant Sciences will be following its historical price patterns.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Roivant Sciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Roivant Sciences may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return (0.08) | Five Day Return 7.27 | Year To Date Return 11.81 | Ten Year Return 22.02 | All Time Return 22.02 |
1 | Does Montes Archimedes Acquisition Have the Potential to Rally 35.12 percent as Wall Street Analysts Expect | 09/10/2024 |
2 | Disposition of 894 shares by Fitzgerald Meghan of Roivant Sciences at 12.12 subject to Rule 16b-3 | 09/12/2024 |
3 | Disposition of 10945 shares by Venker Eric of Roivant Sciences at 11.97 subject to Rule 16b-3 | 09/20/2024 |
4 | Disposition of 250000 shares by Rakhi Kumar of Roivant Sciences at 11.89 subject to Rule 16b-3 | 09/23/2024 |
5 | Disposition of 365551 shares by Gold Daniel Allen of Roivant Sciences at 11.7653 subject to Rule 16b-3 | 09/25/2024 |
6 | Disposition of 876000 shares by Gold Daniel Allen of Roivant Sciences at 11.82 subject to Rule 16b-3 | 09/26/2024 |
7 | Disposition of 2340 shares by Richard Pulik of Roivant Sciences at 11.48 subject to Rule 16b-3 | 09/27/2024 |
8 | Price Over Earnings Overview Roivant Sciences | 10/18/2024 |
9 | Disposition of 100000 shares by Venker Eric of Roivant Sciences at 11.65 subject to Rule 16b-3 | 10/21/2024 |
10 | OrganonDermavantVTAMA1 | 10/29/2024 |
11 | Roivant Sciences Scheduled to Post Earnings on Tuesday | 11/05/2024 |
12 | Roivant Sciences Ltd. Reports Q2 Loss, Misses Revenue Estimates | 11/12/2024 |
13 | Roivant Sciences Ltd. Q2 2024 Earnings Call Transcript | 11/13/2024 |
14 | Rubric Capital Management LPs Strategic Acquisition in GoodRx Holdings Inc | 11/14/2024 |
15 | Im One Of You How Anti-Woke Warrior Vivek Ramaswamy Became A Billionaire At Only 38 | 11/18/2024 |
16 | Disposition of 10945 shares by Venker Eric of Roivant Sciences at 11.49 subject to Rule 16b-3 | 11/20/2024 |
17 | Roivant Sciences Ltd. COO Sells 1,132,000.00 in Stock | 11/25/2024 |
| Begin Period Cash Flow | 1.7 B |
Roivant |
Roivant Sciences Relative Risk vs. Return Landscape
If you would invest 1,177 in Roivant Sciences on August 31, 2024 and sell it today you would earn a total of 92.00 from holding Roivant Sciences or generate 7.82% return on investment over 90 days. Roivant Sciences is currently generating 0.1335% in daily expected returns and assumes 1.6878% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Roivant, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Roivant Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Roivant Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Roivant Sciences, and traders can use it to determine the average amount a Roivant Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0791
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ROIV | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.69 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Roivant Sciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Roivant Sciences by adding it to a well-diversified portfolio.
Roivant Sciences Fundamentals Growth
Roivant Stock prices reflect investors' perceptions of the future prospects and financial health of Roivant Sciences, and Roivant Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Roivant Stock performance.
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 37.25 % | ||||
| Operating Margin | (74.46) % | ||||
| Current Valuation | 3.9 B | ||||
| Shares Outstanding | 727.95 M | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 71.54 X | ||||
| Revenue | 124.8 M | ||||
| Gross Profit | (477.06 M) | ||||
| EBITDA | 4.31 B | ||||
| Net Income | 4.23 B | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 499.75 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.20 X | ||||
| Book Value Per Share | 7.03 X | ||||
| Cash Flow From Operations | (765.27 M) | ||||
| Earnings Per Share | 5.54 X | ||||
| Market Capitalization | 9.24 B | ||||
| Total Asset | 7.22 B | ||||
| Retained Earnings | 576.17 M | ||||
| Working Capital | 6.47 B | ||||
About Roivant Sciences Performance
Evaluating Roivant Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Roivant Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Roivant Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 460.11 | 483.12 | |
| Return On Tangible Assets | 0.61 | 0.64 | |
| Return On Capital Employed | 0.61 | 0.64 | |
| Return On Assets | 0.60 | 0.63 | |
| Return On Equity | 0.73 | 0.77 |
Things to note about Roivant Sciences performance evaluation
Checking the ongoing alerts about Roivant Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Roivant Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Roivant Sciences currently holds about 1.94 B in cash with (765.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Roivant Sciences Ltd. COO Sells 1,132,000.00 in Stock |
- Analyzing Roivant Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Roivant Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Roivant Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Roivant Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Roivant Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Roivant Sciences' stock. These opinions can provide insight into Roivant Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.